PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study.
Activating synthetic ligands for peroxisome proliferator-activated receptor gamma (PPARgamma), such as pioglitazone, are commonly used to treat persons with diabetes mellitus with improvement of insulin resistance. Several reports have clearly demonstrated that PPARgamma ligands could inhibit colorectal cancer cell growth and induce apoptosis. Meanwhile, aberrant crypt foci (ACF) have come to be established as a biomarker of the risk of CRC in azoxymethane-treated mice and rats. In humans, ACF can be detected using magnifying colonoscopy. Previously, CRC and adenoma were used as a target for chemopreventive agents, but it needs a long time to evaluate, however, ACF can be a surrogate marker of CRC even for a brief period. In this clinical study, we investigated the chemopreventive effect of pioglitazone on the development of human ACF as a surrogate marker of CRC. Twenty-nine patients were divided into two groups, 20 were in the endoscopically normal control group and 9 were in the pioglitazone (15 mg/day) group, and ACF and adenoma were examined before and after 1-month treatment. The number of ACF was significantly decreased (5.8 +/- 1.1 to 3.3 +/- 2.3) after 1 month of pioglitazone treatment, however, there was no significant change in the number of crypts/ACF or in the number and size of adenomas. Pioglitazone may have a clinical application as a cancer-preventive drug. This investigation is just a pilot study, therefore, further clinical studies are needed to show that the PPARgamma ligand may be a promising candidate as a chemopreventive agent for colorectal carcinogenesis.
Takahashi
Hirokazu
H
Gastroenterology Division, Graduate School of Medicine, Yokohama City University, 3-9 Fuku-ura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Hosono
Kunihiro
K
Uchiyama
Takashi
T
Sugiyama
Michiko
M
Sakai
Eiji
E
Endo
Hiroki
H
Maeda
Shin
S
Schaefer
Katherine L
KL
Nakagama
Hitoshi
H
Nakajima
Atsushi
A
Carcinogenesis. 1992 Sep;13(9):1509-12
1394832
N Engl J Med. 1998 Oct 29;339(18):1277-84
9791143
J Am Coll Nutr. 2009 Dec;28(6):678-86
20516268
Gastroenterology. 2007 Aug;133(2):393-402
17681160
Int J Cancer. 2008 Sep 1;123(5):991-7
18546290
Mol Cell. 1998 Feb;1(3):465-70
9660931
J Natl Cancer Inst. 2009 Feb 18;101(4):256-66
19211452
Br J Cancer. 2003 Oct 20;89(8):1409-12
14562008
Cancer Lett. 1987 Oct 30;37(2):147-51
3677050
Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):237-41
8990192
N Engl J Med. 2005 Mar 17;352(11):1092-102
15713943
PPAR Res. 2008;2008:785405
18509498
Gastroenterology. 2003 Feb;124(2):361-7
12557142
Cancer Sci. 2003 Nov;94(11):960-4
14611672
J Lab Clin Med. 2002 Jul;140(1):17-26
12080324
Int J Oncol. 2001 Sep;19(3):465-71
11494023
Cancer J. 2002 Sep-Oct;8(5):395-9
12416897
Br J Cancer. 2000 Nov;83(10):1394-400
11044367
Cancer Res. 2000 Feb 15;60(4):1129-38
10706135
Cancer Metastasis Rev. 2003 Mar;22(1):67-82
12716038
Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):906-14
12223437
Cancer. 2009 Dec 15;115(24):5662-71
19827153
J Pharmacol Sci. 2008 Apr;106(4):627-38
18391483
Ann Oncol. 2003;14 Suppl 2:ii3-5
12810450
Gut. 2002 May;50(5):658-64
11950812
Jpn J Cancer Res. 1999 Jan;90(1):75-80
10076568
FEBS Lett. 1999 Jul 16;455(1-2):135-9
10428487
Carcinogenesis. 1998 Jan;19(1):49-53
9472692
J Clin Endocrinol Metab. 2001 May;86(5):2170-7
11344222
Postgrad Med J. 2007 Jun;83(980):414-9
17551074
Int J Cancer. 2006 Nov 15;119(10):2339-46
16858678
Neoplasia. 1999 Oct;1(4):330-9
10935488
Biochem Biophys Res Commun. 2001 Sep 21;287(2):522-9
11554760